Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer
暂无分享,去创建一个
[1] Reinhard Windhager,et al. Galectin-3 Induces a Pro-degradative/inflammatory Gene Signature in Human Chondrocytes, Teaming Up with Galectin-1 in Osteoarthritis Pathogenesis , 2016, Scientific Reports.
[2] J. Jiménez-Barbero,et al. Intra- and intermolecular interactions of human galectin-3: assessment by full-assignment-based NMR. , 2016, Glycobiology.
[3] A. Shivarudrappa,et al. Galectin-3 Immunohistochemical Expression in Thyroid Neoplasms. , 2015, Journal of clinical and diagnostic research : JCDR.
[4] I. Soldatovic,et al. Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature , 2015, Diagnostic Pathology.
[5] B. Zhang,et al. Significance of CK19, TPO, and HBME-1 expression for diagnosis of papillary thyroid carcinoma. , 2015, International journal of clinical and experimental medicine.
[6] J. Kopitz,et al. Human chimera-type galectin-3: defining the critical tail length for high-affinity glycoprotein/cell surface binding and functional competition with galectin-1 in neuroblastoma cell growth regulation. , 2014, Biochimie.
[7] Hui Guo,et al. Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma. , 2014, International journal of clinical and experimental medicine.
[8] K. Kayser,et al. Human osteoarthritic knee cartilage: fingerprinting of adhesion/growth-regulatory galectins in vitro and in situ indicates differential upregulation in severe degeneration , 2014, Histochemistry and Cell Biology.
[9] Robert A. Smith,et al. The expression profiles of the galectin gene family in primary and metastatic papillary thyroid carcinoma with particular emphasis on galectin-1 and galectin-3 expression. , 2014, Experimental and molecular pathology.
[10] J. Kopitz,et al. Context-dependent multifunctionality of galectin-1: a challenge for defining the lectin as therapeutic target , 2013, Expert opinion on therapeutic targets.
[11] C. Maenhaut,et al. Thyroid cancer cell lines: an overview , 2012, Front. Endocrin..
[12] L. L. de Matos,et al. Expression of ck-19, galectin-3 and hbme-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis , 2012, Diagnostic Pathology.
[13] F. Kabukçuoğlu,et al. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions. , 2012, Polish journal of pathology : official journal of the Polish Society of Pathologists.
[14] Christian Fischer,et al. Tumor suppressor p16INK4a: Downregulation of galectin‐3, an endogenous competitor of the pro‐anoikis effector galectin‐1, in a pancreatic carcinoma model , 2010, The FEBS journal.
[15] C. Cohen,et al. Paired box gene 8, HBME‐1, and cytokeratin 19 expression in preoperative fine‐needle aspiration of papillary thyroid carcinoma , 2010, Cancer cytopathology.
[16] Xiong-zeng Zhu,et al. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma , 2010, Journal of Clinical Pathology.
[17] A. Raz,et al. Galectins as Cancer Biomarkers , 2010, Cancers.
[18] A. Bartolazzi,et al. Galectin-3 detection on large-needle aspiration biopsy improves preoperative selection of thyroid nodules: A prospective cohort study , 2010, Annals of medicine.
[19] D. Demydenko,et al. Expression of galectin-1 in malignant tumors. , 2009, Experimental oncology.
[20] F. Pattou,et al. Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. , 2008, Thyroid : official journal of the American Thyroid Association.
[21] A. Krześlak,et al. Expression of cytokeratin 19 in the cytosolic fraction of thyroid lesions: ELISA and Western blot analysis. , 2008, Molecular medicine reports.
[22] J. Kievit,et al. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. , 2008, European journal of endocrinology.
[23] Stephanie L. Lee,et al. Expression of cytokeratin 19 in the diagnosis of thyroid papillary carcinoma by quantitative polymerase chain reaction. , 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[24] F. Pattou,et al. A score based on microscopic criteria proposed for analysis of papillary carcinoma of the thyroid , 2008, Virchows Archiv.
[25] F. Sebag,et al. Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV , 2008, British Journal of Cancer.
[26] P. Alken,et al. Gene‐expression signature of adhesion/growth‐regulatory tissue lectins (galectins) in transitional cell cancer and its prognostic relevance , 2007, Histopathology.
[27] H. Gharib,et al. Thyroid nodules: clinical importance, assessment, and treatment. , 2007, Endocrinology and metabolism clinics of North America.
[28] S. Kwak,et al. Diagnostic Value of Galectin-3, HBME-1, Cytokeratin 19, High Molecular Weight Cytokeratin, Cyclin D1 and p27kip1 in the Differential Diagnosis of Thyroid Nodules , 2007, Journal of Korean medical science.
[29] S. Filetti,et al. Functional characterization of human thyroid tissue with immunohistochemistry. , 2007, Thyroid : official journal of the American Thyroid Association.
[30] David D. Roberts,et al. Proteomic Identification of New Biomarkers and Application in Thyroid Cytology , 2006, Acta Cytologica.
[31] A. Bartolazzi,et al. Galectin‐3 does not reliably distinguish benign from malignant thyroid neoplasms , 2006, Histopathology.
[32] K. Metze,et al. Usefulness of HBME‐1, cytokeratin 19 and galectin‐3 immunostaining in the diagnosis of thyroid malignancy , 2005, Histopathology.
[33] L. Mills,et al. Galectin‐3 is not useful in thyroid FNA , 2005, Cytopathology : official journal of the British Society for Clinical Cytology.
[34] A. Scaloni,et al. A differential proteomic approach to identify proteins associated with thyroid cell transformation. , 2005, Journal of molecular endocrinology.
[35] L. Hegedüs,et al. Thyroid ultrasonography as a screening tool for thyroid disease. , 2004, Thyroid : official journal of the American Thyroid Association.
[36] K. Shroyer,et al. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. , 2004, American journal of clinical pathology.
[37] Isabelle Camby,et al. Galectins and cancer. , 2002, Biochimica et biophysica acta.
[38] M. Niedziela,et al. Galectin-3 is not an universal marker of malignancy in thyroid nodular disease in children and adolescents. , 2002, The Journal of clinical endocrinology and metabolism.
[39] R. Kiss,et al. Immunohistochemical profile of galectin-8 expression in benign and malignant tumors of epithelial, mesenchymatous and adipous origins, and of the nervous system. , 2001, Histology and histopathology.
[40] A. Vecchione,et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions , 2001, The Lancet.
[41] C. Cheung,et al. Immunohistochemical Diagnosis of Papillary Thyroid Carcinoma , 2001, Modern Pathology.
[42] F. Galateau-Sallé,et al. [HBME-1 immunostaining in thyroid pathology]. , 2001, Annales de pathologie.
[43] J. Rosai,et al. Guest Editorial: Two Proposals Regarding the Terminology of Thyroid Tumors , 2000, International journal of surgical pathology.
[44] M. P. Martegani,et al. Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] T. Yoshii,et al. Expression of galectin‐3 in fine‐needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms , 1999, Cancer.
[46] R. Lotan,et al. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. , 1995, The American journal of pathology.
[47] A. Fusco,et al. Expression of galectin‐1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors , 1995, International journal of cancer.
[48] P. Carayon,et al. Immunohistochemical study of thyroid peroxidase in normal, hyperplastic, and neoplastic human thyroid tissues , 1991, Cancer.
[49] Hans-Joachim Gabius,et al. Galectins: their network and roles in immunity/tumor growth control , 2016, Histochemistry and Cell Biology.
[50] B. Zhang,et al. Significance of CK 19 , TPO , and HBME-1 expression for diagnosis of papillary thyroid carcinoma , 2015 .
[51] Z. Baloch,et al. Diagnostic value of differential expression of CK19, galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: An immunohistochemical tissue microarray analysis , 2006, Endocrine pathology.
[52] H. Nagaraja,et al. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors , 2005, Modern Pathology.
[53] H. Gabius,et al. Galectin-1 and galectin-3 in fetal development of bovine respiratory and digestive tracts , 2001, Cell and Tissue Research.
[54] Xiong-zeng Zhu,et al. Diagnostic significance of CK 19 , RET , galectin-3 and HBME-1 expression for papillary thyroid carcinoma , 2022 .